Risk Factors for Secondary Organizing Pneumonia and Acute Fibrinous and Organizing Pneumonia in Patients with COVID-19 Pneumonia
Alisa Aikwanich,Dararat Eksombatchai,Tananchai Petnak,Tanapat Tassaneeyasin,Viboon Boonsarngsuk
DOI: https://doi.org/10.2147/idr.s481540
2024-11-13
Infection and Drug Resistance
Abstract:Alisa Aikwanich, 1 Dararat Eksombatchai, 1 Tananchai Petnak, 1 Tanapat Tassaneeyasin, 2 Viboon Boonsarngsuk 1 1 Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand; 2 Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand Correspondence: Dararat Eksombatchai, Division of Pulmonary and Pulmonary Critical Care Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Bangkok, 10400, Thailand, Tel +66 2 201 1619, Email Purpose: Secondary organizing pneumonia (OP) and acute fibrinous and organizing pneumonia (AFOP) are frequently observed in cases of COVID-19 pneumonia. Nevertheless, the identification of risk factors related to OP/AFOP and their impact on patient outcomes remain inadequately elucidated. Patients and Methods: This retrospective study aimed to identify risk factors associated with OP/AFOP in patients with COVID-19 pneumonia and to compare clinical outcomes between patients with and without OP/AFOP. The study included hospitalized patients with COVID-19 pneumonia admitted between July 1 and September 30, 2021. Factors associated with OP/AFOP were identified using multivariable regression analysis. Additionally, a multivariable Cox proportional hazard model was used to evaluate the association of OP/AFOP with 90-day mortality. Results: Among the 666 hospitalized patients with COVID-19 pneumonia, 53 (8%) developed OP/AFOP during their admission. When compared to patients younger than 50 years old, those aged 50– 70 and over 70 years old exhibited an increased risk of developing OP/AFOP, with adjusted odds ratios (aOR) of 3.87 (95% CI, 1.24– 12.11; P=0.02) and 5.74 (95% CI, 1.80– 18.27; P=0.003), respectively. Other factors associated with OP/AFOP included a history of diabetes mellitus (aOR 2.37; 95% CI, 1.27– 4.44; P=0.01) and patients with oxygen saturation at admission below 88% (aOR 4.52; 95% CI, 1.22– 16.67; P=0.02). Furthermore, the presence of OP/AFOP was correlated with an increased risk of various complications, such as respiratory failure, acute kidney injury, secondary infections, pneumothorax, pneumomediastinum, and pulmonary embolism. Lastly, patients with OP/AFOP exhibited significantly higher 90-day mortality (adjusted hazard ratio 3.40; 95% CI, 1.68– 6.92; P=0.001) compared to those without OP/AFOP. Conclusion: We identified factors associated with an increased risk of OP/AFOP in patients with COVID-19 pneumonia, which included age ≥ 50 years, a history of DM, and hypoxemia on admission (SpO2 < 88%). Furthermore, our study revealed that OP/AFOP was significantly linked to higher 90-day mortality. Keywords: COVID-19, pneumonia, organizing pneumonia, acute fibrinous and organizing pneumonia, risk factor, mortality, complication The novel Coronavirus Disease 2019 (COVID-19), caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), poses a significant global public health and economic burden. 1 Amid the delta variant pandemic, pneumonia developed in 50–90% of COVID-19 patients. 2 During the late phase of COVID-19 pneumonia, typically occurring after 2 weeks of infection, secondary organizing pneumonia (OP) and acute fibrinous and organizing pneumonia (AFOP) may emerge and significantly contribute to the majority of COVID-19 respiratory complications. The pathogenesis of OP originates with alveolar injury leading to an accumulation of fibrin and fibroblast, then followed by the formation of intra-alveolar buds of granulation tissue. On the other hand, AFOP is a more severe pattern of lung injury with hallmark histological findings include intra-alveolar "fibrin balls" accumulation within the alveolar spaces. 3 Organizing pneumonia and AFOP can be idiopathic or secondary to infections, connective tissue diseases, drug toxicity, or occupational exposures. 4 Post-mortem studies of patients with COVID-19 pneumonia have demonstrated a histological pattern of OP/AFOP in individuals who experienced symptoms lasting for more than 20 days. In contrast, in patients in the early phase of the disease, characterized by symptoms lasting ≤10 days, a predominantly diffuse alveolar damage (DAD) pattern was evident. 5,6 In addition, evidence of the histopathological transition of lung parenchyma from DAD to AFOP during the later stage of COVID-19 pneumonia has been documented. 7 Nowadays, systemic corticosteroids remain the mainstay of treatment for secondary OP/AFOP in COVID-19 pneumonia. While the majority of patients with secondary OP/AFOP can resolve spontaneously or exhibit an excellent respo -Abstract Truncated-
pharmacology & pharmacy,infectious diseases